Physician

Theodros Mengesha, MD

According to 2025 Medicare claims, Theodros Mengesha, MD (NPI: 1184771909) practices neurology in the Huntsville, AL market, with the plurality of this provider's patient population coming from Madison, AL. This provider's primary affiliated billing organization is TENNESSEE VALLEY NEUROLOGICAL ASSOCIATES PC (NPI: 1538696802; TIN: 82-1429617) and primary practice location at 35758-9545. Mengesha is affiliated with the Huntsville ACO (ACO ID: A3579), participating under the MSSP model.

Mengesha's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 959 traditional Medicare patients, billed 4,373 HCPCS/CPT codes, and received $514,644 in Medicare payments. The top billing code was 95819 (Measurement of brain wave activity (eeg), awake and asleep). Part D data shows 8,310 prescription claims across 1,023 beneficiaries totaling $2,336,963 in drug costs, led by Privigen (Immun Glob G(Igg)/Pro/Iga 0-50). 2023 DME data shows 24 claims. Open Payments data shows 264 records totaling $24,212. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $187,955 and ending at $514,644. Concurrently, Part D prescription costs have risen steadily, from $1,451,035 to $2,336,963. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $7,744 and ending at $466.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,126	2,388	$187,955
2016	1,242	2,906	$236,126
2017	1,211	2,527	$222,109
2018	1,491	3,407	$321,331
2019	1,389	2,807	$266,160
2020	1,145	2,329	$210,589
2021	979	2,160	$220,849
2022	875	1,775	$174,314
2023	924	1,919	$190,108
2024	959	4,373	$514,644

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	607	4,815	$1,451,035
2016	637	5,086	$1,744,289
2017	641	5,371	$1,773,055
2018	785	6,847	$2,250,761
2019	839	7,477	$2,728,935
2020	864	7,937	$2,830,550
2021	910	8,466	$2,831,776
2022	855	7,959	$2,685,304
2023	871	7,875	$2,570,947
2024	1,023	8,310	$2,336,963

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	45	$1,061
2016	N/R	11	$165
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	11	$1,329
2020	N/R	23	$3,234
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	24	$4,067
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
95819	Measurement of brain wave activity (eeg), awake and asleep	204	208	$191
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	185	185	$149
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	162	169	$124
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	107	109	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	701	1,140	$81

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Privigen	Immun Glob G(Igg)/Pro/Iga 0-50	12	360	$296,853
Gammaked	Immune Globul G/Gly/Iga Avg 46	39	1,092	$186,056
Rebif Rebidose	Interferon Beta-1a/Albumin	13	364	$132,907
Aimovig Autoinjector	Erenumab-Aooe	141	5,268	$129,065
Lamictal Xr	Lamotrigine	11	510	$61,255

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	263	$4,930	UCB, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$19,282	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Theodros Mengesha, MD?

Tedicare shows public-source Medicare data for Theodros Mengesha, MD (NPI 1184771909), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Theodros Mengesha, MD have ACO affiliation data?

Theodros Mengesha, MD is shown with ACO affiliation data for Huntsville ACO (MSSP, ACO ID A3579).

What billing organization is linked to Theodros Mengesha, MD?

Theodros Mengesha, MD is linked to TENNESSEE VALLEY NEUROLOGICAL ASSOCIATES PC (billing NPI 1538696802) in the available physician profile data.

Does Theodros Mengesha, MD have Open Payments data?

Theodros Mengesha, MD has 264 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.